ACETAZOLAMIDE SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C4H5N4O3S2.Na
Molecular Weight	244.227
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].CC(=O)NC1=NN=C(S1)S([NH-])(=O)=O

InChI

InChIKey=MRSXAJAOWWFZJJ-UHFFFAOYSA-M

InChI=1S/C4H6N4O3S2.Na/c1-2(9)6-3-7-8-4(12-3)13(5,10)11;/h1H3,(H3,5,6,7,9,10,11);/q;+1/p-1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/12945s037,038lbl.pdf

Acetazolamide, usually sold under the trade name Diamox in some countries. DIAMOX is used for adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. DIAMOX is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness despite gradual ascent. DIAMOX is an enzyme inhibitor that acts specifically on carbonic anhydrase, the enzyme that catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In the eye, this inhibitory action of acetazolamide decreases the secretion of aqueous humor and results in a drop in intraocular pressure, a reaction considered desirable in cases of glaucoma and even in certain non-glaucomatous conditions. Evidence seems to indicate that DIAMOX has utility as an adjuvant in treatment of certain dysfunctions of the central nervous system (e.g., epilepsy). The diuretic effect of DIAMOX is due to its action in the kidney on the reversible reaction involving hydration of carbon dioxide and dehydration of carbonic acid. The result is renal loss of HCO3 ion, which carries out sodium, water, and potassium. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Carbonic anhydrase II 88 Target ID: CHEMBL205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11430635	Inhibitor 8297
Carbonic anhydrase IV 33 Target ID: CHEMBL3729 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=18336310	Inhibitor 8297
Carbonic anhydrase XII 30 Target ID: CHEMBL3242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=18336310	Inhibitor 8297
Carbonic anhydrase I 62 Target ID: CHEMBL261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11430635	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Open-angle glaucoma 51 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/12945s037,038lbl.pdf	Palliative		Approved 8429	DIAMOX Approved Use For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. DIAMOX is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness despite gradual ascent. Launch Date 1953
Acute mountain sickness 5 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/12945s037,038lbl.pdf	Preventing		Approved 8429	DIAMOX Approved Use For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. DIAMOX is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness despite gradual ascent. Launch Date 1953

C_max

Value	Dose	Co-administered	Analyte	Population
776 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27300254	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:		ACETAZOLAMIDE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1313 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27300254	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:		ACETAZOLAMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
52130 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27300254	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:		ACETAZOLAMIDE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6735 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27300254	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:		ACETAZOLAMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
42.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27300254	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:		ACETAZOLAMIDE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27300254	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:		ACETAZOLAMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
5% REVIEW https://link.springer.com/chapter/10.1007/978-1-4471-2434-4_1	unknown, oral		ACETAZOLAMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
250 mg 4 times / day multiple, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9881560/	unhealthy, 21–80 years n = 52 Health Status: unhealthy Condition: elevated intraocular pressure Age Group: 21–80 years Sex: M+F Population Size: 52 Sources: https://pubmed.ncbi.nlm.nih.gov/9881560/	Disc. AE: Leukopenia... AEs leading to discontinuation/dose reduction: Leukopenia Sources: https://pubmed.ncbi.nlm.nih.gov/9881560/
500 mg 4 times / day multiple, oral Studied dose Dose: 500 mg, 4 times / day Route: oral Route: multiple Dose: 500 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32082641/	unhealthy, 70 years n = 1 Health Status: unhealthy Condition: Diabetes \| Chronic Renal Failure Age Group: 70 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/32082641/	Other AEs: Metabolic acidosis, Coma... Other AEs: Metabolic acidosis (grade 3) Coma Sources: https://pubmed.ncbi.nlm.nih.gov/32082641/

AEs

AE	Significance	Dose	Population
Leukopenia	Disc. AE	250 mg 4 times / day multiple, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9881560/	unhealthy, 21–80 years n = 52 Health Status: unhealthy Condition: elevated intraocular pressure Age Group: 21–80 years Sex: M+F Population Size: 52 Sources: https://pubmed.ncbi.nlm.nih.gov/9881560/
Coma		500 mg 4 times / day multiple, oral Studied dose Dose: 500 mg, 4 times / day Route: oral Route: multiple Dose: 500 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32082641/	unhealthy, 70 years n = 1 Health Status: unhealthy Condition: Diabetes \| Chronic Renal Failure Age Group: 70 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/32082641/
Metabolic acidosis	grade 3	500 mg 4 times / day multiple, oral Studied dose Dose: 500 mg, 4 times / day Route: oral Route: multiple Dose: 500 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32082641/	unhealthy, 70 years n = 1 Health Status: unhealthy Condition: Diabetes \| Chronic Renal Failure Age Group: 70 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/32082641/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587	inhibitor 1767	inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2C19 1478 CYP2E1 882 OAT1 599 OAT2 145 OAT3 642 OAT4 146 OATP1B1 788 OATP1B3 706 BSEP 402 MRP2 383 MRP3 157 MRP4 204	P-gp 1537

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDIwIn19	no [IC50 >10 uM]
CYP2A6 739	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDIwIn19	no [IC50 >10 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDIwIn19	no [IC50 >10 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDIwIn19	no [IC50 >10 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMjAifX0%3D	no [IC50 >10 uM]
CYP2E1 970	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDIwIn19	no [IC50 >10 uM]
BSEP 403	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP2 475	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP3 207	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP4 238	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
OAT2 147	inhibitor 3277 Sources: https://transportal.compbio.ucsf.edu/compounds/acetazolamide/, https://pubmed.ncbi.nlm.nih.gov/14610216/	no [IC50 >5000 uM]
OAT4 146	inhibitor 3277 Sources: https://transportal.compbio.ucsf.edu/compounds/acetazolamide/, https://pubmed.ncbi.nlm.nih.gov/14610216/	weak [IC50 425 uM]
OAT3 644	inhibitor 3277 Sources: https://transportal.compbio.ucsf.edu/compounds/acetazolamide/, https://pubmed.ncbi.nlm.nih.gov/14610216/	weak [IC50 816 uM]
OAT1 603	inhibitor 3277 Sources: https://transportal.compbio.ucsf.edu/compounds/acetazolamide/, https://pubmed.ncbi.nlm.nih.gov/14610216/	yes [IC50 75 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo	yes
OATP1B1 803	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes
OATP1B3 715	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16882549/	weak

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY562106	https://www.001chemical.com/chem/59-66-5
3B Scientific (Wuhan) Corp	3B3-007384	http://www.3bsc.com/index/pro_info.php?id=29891
AA Blocks	AA003NJP	https://www.aablocks.com/goods/Goods/detail?id=AA003NJP
AHH Chemical co.,ltd	MT-46429	http://www.ahhchemical.com/product/MT-46429.html
AK Scientific, Inc. (AKSCI)	H501	http://www.aksci.com/item_detail.php?cat=H501
AK Scientific, Inc. (AKSCI)	J10059	http://www.aksci.com/item_detail.php?cat=J10059
Aaron Chemicals	AR003OBH	http://www.aaronchem.com/59-66-5
Acadechem	ACDS-028355	http://www.acadechemical.com/product/103054
Achemica	ACMC-20gwkd	http://www.achemica.com/prodinfo/?id=146724
Achemo Scientific Limited	AC-17803	http://www.achemo.com/product_view.asp?ID=7693
Achemtek	0104-010260	http://www.achemtek.com/59-66-5
Adooq BioScience	A15859	https://www.adooq.com/acetazolamide.html
Alfa Aesar	L07562	https://www.alfa.com/en/catalog/L07562/
Alinda	ALBB-023617	http://alinda.ru/finechem_en_.html?i=ALBB-023617
Alsachim	791	http://www.alsachim.com/product-C1104-glo.bal-view.html
Angene	AGN-PC-07Y45H	http://www.angenechemical.com/productshow/AGN-PC-07Y45H.html
Ark Pharm	AK324920	http://www.arkpharminc.com/products/59-66-5.html
Aurum Pharmatech LLC	R1055	http://www.Aurumpharmatech.com/Product/ProductDetails/R1055
Avantor Inc	101094-196	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101094-196
Avantor Inc	TCA2598-100G	https://us.vwr.com/store/product/16809177/acetazolamide-98-0-by-hplc-titration-analysis
Avantor Inc	TCA2598-25G	https://us.vwr.com/store/product/16809177/acetazolamide-98-0-by-hplc-titration-analysis
BOC Sciences	1189904-01-5	https://www.bocsci.com/acetazolamide-d3-cas-1189904-01-5-item-482235.html
BenchChem	B516962	https://www.benchchem.com/product/b516962
BioChemPartner	BCP29616	http://www.biochempartner.com/59-66-5-BCP29616
BioSynth	Q-200579	https://www.biosynth.com/en/products/life-science/dyes-stains-indicators-labels/products/Q-200579.html
BioSynth	Q-200580	https://www.biosynth.com/products/biochemistry/other-biochemicals/products/Q-200580.html
Capot Chemical	12858	http://www.capotchem.com/en/12858.htm
Capot Chemical	PubChem12858	http://www.capotchem.com/en/12858.htm
Chem Scene	CS-3568	http://www.chemscene.com/59-66-5.html
ChemMol	30102486	http://www.chemmol.com/chemmol/30102486.html
ChemMol	49400302	http://www.chemmol.com/chemmol/49400302.html
ChemMol	99115260	http://www.chemmol.com/chemmol/99115260.html
Chemenu	CM110359	http://www.chemenu.com/products/CM110359
Chemspace	CSSB00000693915	https://chem-space.com/CSSB00000693915
Clearsynth	CS-EG-00018	https://www.clearsynth.com/en/CSEG00018.html
Clearsynth	CS-ER-02333	https://www.clearsynth.com/en/CSER02333.html
Clearsynth	CS-O-07116	https://www.clearsynth.com/en/CSO07116.html
DC Chemicals	DC8978	http://www.dcchemicals.com/product_show-Acetazolamide.html
Debye Scientific	DB-053437	http://www.debyesci.com/cas_59-66-5.html
Enamine	Z277559108	https://www.enaminestore.com/catalog/Z277559108
FondChemical	FDB-1470	http://www.fondchemical.com/cpshow_cid_8_pid_658.html
Glentham Life Sciences	GP7201	http://www.glentham.com/products/product/GP7201/
Hairui	HR132338	http://www.hairuichem.com/en/product/59-66-5.html
LGC Standards	LGCFOR0648.00	https://www.lgcstandards.com/US/en/p/LGCFOR0648.00
LGC Standards	MM0648.00	https://www.lgcstandards.com/US/en/p/MM0648.00
Lab Network	LN00224818	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00224818
Matrix Scientific	155283	https://www.matrixscientific.com/155283.html
MedChem Express	HY-B0782	https://www.medchemexpress.com/Acetazolamide.html
MolPort	MolPort-001-783-578	https://www.molport.com/shop/molecule-link/MolPort-001-783-578
Molcore	MC562106	https://www.molcore.com/product/59-66-5
OChem	28	http://www.ocheminc.com/index.php?act=psearch&pid=003A105
Oakwood	358074	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=164831&ExtHyperLink=1
Parchem	10799	http://www.parchem.com/chemical-supplier-distributor/Acetazolamide-000799.aspx
Sigma-Aldrich	97582_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/97582?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A0100000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/a0100000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	PHR1908_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/phr1908?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A6011_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a6011?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1005004_USP	https://www.sigmaaldrich.com/catalog/product/usp/1005004?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S012698	http://www.sinfoobiotech.com/product/1016096
Smolecule	S516962	http://www.smolecule.com/products/s516962
Smolecule	S809719	https://www.smolecule.com/products/s809719
TCI (Tokyo Chemical Industry)	A2598	http://www.tcichemicals.com/eshop/en/us/commodity/A2598/index.html
THE BioTek	bt-257097	https://www.thebiotek.com/product/inhibitors/bt-257097
Tocris	6742	https://www.tocris.com/products/acetazolamide_6742
VladaChem	VL276587-5G	https://www.vladachem.com/product.php?products=59-66-5
Yuhao Chemical	LL0043	http://www.chemyuhao.com/59-66-5.html
abcr GmbH	AB178374	http://www.abcr.com/shop/en/AB178374
eNovation Chemicals	D489198	https://www.enovationchem.com/ProductDetails.asp?ProductID=D489198
iChemical	EBD55026	http://www.ichemical.com/chemicals/cas-59-66-5
mcule	MCULE-4029778803	https://mcule.com/MCULE-4029778803/

PubMed

Title	Date	PubMed
Renal failure associated with acetazolamide therapy for glaucoma.	1975 Apr	1124417
[Salicylism and glaucoma: reciprocal augmentation of the toxicity of acetazolamide and acetylsalicylic acid].	1999 Feb	10221197
Acetazolamide-responsive periodic ataxia induced by amiodarone.	1999 Mar	10091644
Acetazolamide-induced Gerstmann syndrome.	1999 Oct-Nov	10692744
Acetazolamide and enalapril combination offers complete protection from nitric oxide-deficient stroke in stroke-prone spontaneously hypertensive rats.	2000 Jun	10816334
Cerebellar Ataxia.	2000 May	11096749
Management strategies for refractory localization-related seizures.	2001	11520319
[Therapeutic use of potassium citrate].	2001	11475849
Herpes simplex virus bullous keratitis misdiagnosed as a case of pseudophakic bullous keratopathy with secondary glaucoma: an unusual presentation.	2001	11472638
Diuretic therapy for newborn infants with posthemorrhagic ventricular dilatation.	2001	11406041
Vasoconstrictive drugs increase carbonic anhydrase I in vascular smooth muscle while vasodilating drugs reduce the activity of this isozyme by a direct mechanism of action.	2001	11392054
[A case of potassium-sensitive periodic paralysis with cardiac dysrhythmia controlled with imipramine and acetazolamide].	2001 Apr	11360478
What factors are related to impairment of cerebrovascular reserve before and after arteriovenous malformation resection? A cerebral blood flow study using xenon-enhanced computed tomography.	2001 Apr	11322430
Benign intracranial hypertension: correlation of cerebral blood flow with disease severity.	2001 Apr	11311474
Calcification in the planula and polyp of the hydroid Hydractinia symbiolongicarpus (Cnidaria, Hydrozoa).	2001 Aug	11533115
Acetazolamide poisoning in a toddler.	2001 Aug	11532068
Grossly false applanation tonometry associated with interface fluid in susceptible LASIK patients.	2001 Aug	11530785
Evaluation of blood flow in the cerebral microcirculation: analysis of the refill kinetics during ultrasound contrast agent infusion.	2001 Aug	11527592
[A coronary artery bypass grafting using cardiopulmonary bypass with intraaortic balloon pumping in patient with low cardiac function combined with cerebral vascular disease].	2001 Aug	11517550
Minocycline and Pseudotumor cerebri: The well-known but well-kept secret.	2001 Aug	11491116
Cerebrovascular reserve in patients with carotid occlusive disease assessed by stable xenon-enhanced ct cerebral blood flow and transcranial Doppler.	2001 Aug	11486110
Carbonic anhydrase isozyme distribution and characterization in metabolic fiber types of the dorsal levator muscle of the blue crab, Callinectes sapidus.	2001 Aug 1	11479903
Beta-adrenergic blocker therapy and the trabecular meshwork.	2001 Feb	11372544
Effect of familial hypertension on glomerular hemodynamics and tubulo-glomerular feedback after uninephrectomy.	2001 Feb	11243302
Indapamide, a thiazide-like diuretic, decreases bone resorption in vitro.	2001 Feb	11204436
Long-term follow-up of asymptomatic patients with major artery occlusion: rate of symptomatic change and evaluation of cerebral hemodynamics.	2001 Feb	11156763
In vivo evidence for K(Ca) channel opening properties of acetazolamide in the human vasculature.	2001 Jan	11159693
Theta rhythm of hippocampal CA1 neuron activity: gating by GABAergic synaptic depolarization.	2001 Jan	11152726
Pharmacological prevention of acute mountain sickness. Same ascent rates must be used to assess effectiveness of different doses of acetazolamide.	2001 Jan 6	11141168
Pharmacological prevention of acute mountain sickness. Many climbers and trekkers find acetazolamide 500 mg/day to be useful.	2001 Jan 6	11141167
Preferential acetazolamide-induced vasodilation based on vessel size and organ: confirmation of peripheral vasodilation with use of colored microspheres.	2001 Jul	11515988
Liquid and ion transport by fetal airway and lung epithelia of mice deficient in sodium-potassium-2-chloride transporter.	2001 Jul	11472970
Cerebral vasoreactivity and internal carotid artery flow help to identify patients at risk for hyperperfusion after carotid endarterectomy.	2001 Jul	11441203
Reliable measurement of mouse intraocular pressure by a servo-null micropipette system.	2001 Jul	11431452
High-altitude illness.	2001 Jul 12	11450659
Extracellular carbonic anhydrase in the dogfish, Squalus acanthias: a role in CO2 excretion.	2001 Jul-Aug	11436132
Medical support on a Himalayan expedition.	2001 Jun	11464421
Acetazolamide in women with catamenial epilepsy.	2001 Jun	11422329
Langerhans' cell histiocytosis presenting as intracranial hypertension.	2001 Jun	11417606
Serous macular detachments in a patient with IgM paraproteinemia: an optical coherence tomography study.	2001 Jun	11405848
Correlation of optic nerve head tomography with visual field sensitivity in papilledema.	2001 Jun	11381051
Pharmacological enhancement of synaptic efficacy, spatial learning, and memory through carbonic anhydrase activation in rats.	2001 Jun	11356917
Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A.	2001 Jun	11353725
Model of ionic transport for bovine ciliary epithelium: effects of acetazolamide and HCO.	2001 Jun	11350747
Sporadic late onset paroxysmal cerebellar ataxia in four unrelated patients: a new disease?	2001 Mar	11355155
Characterization of carbonic anhydrase from Neisseria gonorrhoeae.	2001 Mar	11248679
Revisiting the question, "is the acetazolamide test valid for quantitative assessment of maximal cerebral autoregulatory vasodilation?".	2001 May	11340242
Identification and localization of acid-base transporters in the conjunctival epithelium.	2001 May	11311044

Patents

Sample Use Guides

In Vivo Use Guide

Glaucoma: The recommended dosage is 1 capsule (500 mg) two times a day. Usually 1 capsule is administered in the morning and 1 capsule in the evening. It may be necessary to adjust the dose, but it has usually been found that dosage in excess of 2 capsules (1 g) does not produce an increased effect Acute Mountain Sickness: Dosage is 500 mg to 1000 mg daily, in divided doses using tablets or extended-release capsules as appropriate. In circumstances of rapid ascent, such as in rescue or military operations, the higher dose level of 1000 mg is recommended

Route of Administration: Oral

In Vitro Use Guide

In both, piriform and entorhinal cortices (PC and EC, respectively), acetazolamide (10 uM): (i) reduced the duration and the interval of ccurrence of ictal discharges along with the associated ripples and fast ripples; (ii) decreased the interval of occurrence of interictal discharges and the rates of associated fast ripples; and (iii)diminished the duration and amplitude of pharmacologically isolated GABAergic events while increasing their interval of occurrence.

Name

Type

Language

ACETAZOLAMIDE SODIUM

Common Name

English

ACETAZOLAMIDE SODIUM SALT [MI]

Common Name

English

ACETAZOLAMIDE SODIUM [GREEN BOOK]

Common Name

English

ACETAZOLAMIDE SODIUM [JAN]

Common Name

English

Acetazolamide sodium [WHO-DD]

Common Name

English

ACETAZOLAMIDE SODIUM [MART.]

Common Name

English

SODIUM ACETAZOLAMIDE

Common Name

English

ACETAZOLAMIDE SODIUM [ORANGE BOOK]

Common Name

English

N-(5-Sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide monosodium salt

Common Name

English

ACETAZOLAMIDE SODIUM [VANDF]

Common Name

English

VETAMOX

Brand Name

English

ACETAMIDE, N-(5-(AMINOSULFONYL)-1,3,4-THIADIAZOL-2-YL)-, MONOSODIUM SALT

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C448